Form 4: IMMUNIC Director Tamar Howson Granted 150,000 Stock Options

IMMUNIC, Inc. Director Tamar D. Howson was granted 150,000 stock options with an exercise price of $0.7729, vesting monthly over one year.

Summary

• IMMUNIC, Inc. (IMUX) Director Tamar D. Howson was granted 150,000 stock options on June 5, 2025.
• The options have an exercise price of $0.7729 per share.
• These options will vest in monthly increments over a period of one year from the grant date.
• The options expire on June 5, 2035.
• Following this transaction, Ms. Howson directly beneficially owns 150,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholders, but it is a routine compensation matter and not indicative of significant operational or financial news.

Positives

• The grant of stock options to a director, Tamar D. Howson, aligns her interests with those of the shareholders, incentivizing long-term company performance.

Negatives

• No negative aspects are directly discernible from this routine insider transaction filing.

Risks

• This Form 4 filing does not contain information regarding company-specific risks.

Future Outlook

The granted stock options will vest in monthly increments over the next year, aligning the director's future compensation with the company's performance.

Industry Context

Granting stock options to directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain talent and align leadership incentives with shareholder value creation.

Comparison to Industry Standards

• While granting stock options is a standard form of director compensation, this document does not provide sufficient detail to compare the specific terms (e.g., number of options relative to director's total compensation, exercise price relative to market price at grant) against industry benchmarks or specific comparable companies.

Related Party Transactions

• The grant of 150,000 stock options to Tamar D. Howson, a Director of IMMUNIC, Inc., constitutes a related party transaction as it involves a transaction between the company and an insider.

Stakeholder Impact

• Shareholders: The option grant aims to align the director's financial interests with shareholder value creation, potentially leading to more focused decision-making for long-term growth.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• The stock options will vest in monthly increments over the next year.

Key Dates

Keywords

IMMUNIC, IMUX, Form 4, SEC filing, insider transaction, stock options, director compensation, beneficial ownership, equity grant